<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877693</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10163</org_study_id>
    <nct_id>NCT02877693</nct_id>
  </id_info>
  <brief_title>A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging</brief_title>
  <acronym>ASIA MRI ICD</acronym>
  <official_title>A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the clinical performance of the St. Jude Medical™ MR Conditional ICD System in
      patients undergoing an elective thoracic MRI scan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is a prospective, multicenter, 2-phase, single arm, Asian study.

        -  In the 1st phase patients will be enrolled at least 60 days post successful implant with
           a St. Jude Medical™ MR Conditional ICD System approved for thoracic scan with 1.5 Tesla
           MRI scanning machines.

        -  In the 2nd phase patients will be enrolled at least 60 days post successful implant with
           a St. Jude Medical™ MR Conditional ICD System approved* for thoracic scan with 3.0 Tesla
           MRI scanning machines.

             -  NOTE: The 2nd phase of this study will start only after receiving appropriate
                regulatory approval for MRI labelling at 3.0T and phase 1 enrollment has completed.
                The Sponsor will notify each ethics committee and site when Phase 2 may begin.
                Patient can be enrolled only in one of the two phases of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from MRI-scan related complications* related to St. Jude Medical™ MR Conditional ICD System</measure>
    <time_frame>from MRI scan visit to 1 month post-MRI scan visit</time_frame>
    <description>*A complication is a serious adverse device effect (SADE) that requires an invasive intervention or leads to death.
The primary endpoint analysis will be performed for each study phase separately.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>ICD</condition>
  <condition>Tachycardia</condition>
  <arm_group>
    <arm_group_label>Thoracic MRI Scan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic MRI Scan</intervention_name>
    <description>is to demonstrate the MRI scan will not adversely affect the functionality of the ICD system. To do so, the ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.</description>
    <arm_group_label>Thoracic MRI Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is pectorally implanted with St. Jude Medical™ MR Conditional ICD System for
             at least 60 days

          2. Subject is willing to undergo an elective MRI scan without sedation NOTE: Antianxiety
             agents (e.g. minor tranquilizers, etc.) may be used as long as the patient can
             communicate with site personnel during the MRI scan

          3. Subject's ventricular bipolar capture threshold is stable &lt; 2.5V @ 0.5ms

          4. Subject's ventricular sensing is measurable (patient has underlying rhythm &gt; 30bpm)
             and the sensing amplitude is stable &gt; 4mV

          5. Subject is able to provide informed consent for study participation (legal guardian or
             legally authorized representative is NOT acceptable)

          6. Subject is willing and able to comply with the prescribed follow-up tests and
             procedures

          7. Subject is not contraindicated for an MRI scan (per the MRI Screening Form)

        Exclusion Criteria:

          1. Subject is pacemaker dependent

          2. Subject has a non SJM MRI compatible endocardial lead implanted or capped

          3. Subject has another existing active implanted medical device, e.g., neurostimulator,
             infusion pump, etc. that has MR labeling that will not allow the MRI scans per this
             protocol to be completed.

          4. Subject has a high voltage lead revision incidence &lt; 60 days of the enrollment visit

          5. Subject has other non-MRI compatible device or material implanted NOTE: MRI compatible
             knee replacements, hip replacements, stents, etc. may be included as long as the
             labeling of these devices allow MRI scans conducted per this protocol NOTE: MRI
             compatible mechanical, prosthetic, and bioprosthetic heart valves may be included as
             long as the labeling of these devices allow for MRI scans conducted per this protocol
             NOTE: Non-removable dental implants may be included

          6. Subject has a lead extender, adaptor, or capped/abandoned lead

          7. Subject is enrolled or intend to participate in a clinical drug and/or device study
             (investigational device, investigational drug, new indication for a device or drug or
             additional testing beyond standard of care procedures), which could confound the
             results of this trial as determined by SJM.

          8. Subject is pregnant or planning to become pregnant during the duration of the
             subject's participation in the study

          9. Subject has a life expectancy of less than 12 months due to any condition

         10. Subject has exclusion criteria required by local law (e.g., age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Kim</last_name>
    <role>Study Director</role>
    <affiliation>St. Jude Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pallavi Singh</last_name>
    <phone>+91 9167077454</phone>
    <email>pallavi.singh@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sumit Anand</last_name>
    <phone>+91 11 42600161</phone>
    <email>sumit.anand@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medanta-The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praveen Chandra</last_name>
      <phone>91-9810125370</phone>
      <email>Praveen.chandra@medanta.org</email>
    </contact>
    <investigator>
      <last_name>Praveen Chandra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education &amp; Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Vijayvergiya</last_name>
      <phone>+919815221856</phone>
      <email>rajeshvijay999@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Rajesh Vijayvergiya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BLK Super Speciality Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhash Chandra</last_name>
      <phone>91-1130653932</phone>
      <email>subhash.chandra@blkhospital.com</email>
    </contact>
    <investigator>
      <last_name>Subhash Chandra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Max Super Specialty Hospital</name>
      <address>
        <city>Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanita Arora</last_name>
      <phone>+91-9871879994</phone>
      <email>vanita.arora@maxhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Vanita Arora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pushpawati Singhania Research Institute</name>
      <address>
        <city>Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarlochan Singh Kler</last_name>
      <phone>+91-9810081850</phone>
      <email>tskler1317@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tarlochan Singh Kler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debasis Ghosh</last_name>
      <phone>91-9831034078</phone>
      <email>debgkol@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Debasis Ghosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Batra Hospital &amp; Medical Research Centre</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Upendra Kaul</last_name>
      <phone>+91-9811150518</phone>
      <email>kaul.upendra@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Upendra Kaul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fortis Flt. Lt. Rajan Dhall Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>National Heart Institute</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medanta Medicity Hospital</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balbir Singh</last_name>
      <phone>+91-9811102598</phone>
      <email>Balbir.Singh@Medanta.org</email>
    </contact>
    <investigator>
      <last_name>Balbir Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chennapragada Sridevi</last_name>
      <phone>91-9866101054</phone>
      <email>dr_csridevi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Chennapragada Sridevi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asian Heart Institute</name>
      <address>
        <city>Mumbai</city>
        <zip>400051</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Dora</last_name>
      <phone>+91-9920069719</phone>
      <email>kskdora@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Santosh Dora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Escorts Heart Institute and Research Centre</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aparna Jaswal</last_name>
    </contact>
    <investigator>
      <last_name>Aparna Jaswal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongmin Kim</last_name>
      <email>kdongmin@dankook.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dongmin Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cha Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JungHoon Sung</last_name>
      <email>atropin5@cha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>JungHoon Sung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choi Eue Keun</last_name>
      <email>choiek417@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Choi Eue Keun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh Yong Seog</last_name>
      <email>oys@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Oh Yong Seog</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bo Young Joung</last_name>
      <email>cby6908@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Bo Young Joung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Serdang</name>
      <address>
        <city>Kajang</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Fazli Bin Abdul Aziz</last_name>
      <email>afazli@upm.edu.my</email>
    </contact>
    <investigator>
      <last_name>Ahmad Fazli Bin Abdul Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Tarlochan Singh Kler, Praveen Chandra, Chandrakant Chavan, Rajesh Vijayvergiya, Subhash Chandra, Anoop Gupta, Sridevi Chennapragada, Joung Bo Young, Mona Bhatia, Choi Eue Keun, Vanita Arora, Tom Devasia, Upendra Kaul, Sumit Anand, Kartikeya Bhargava. Initial experience of thoracic Magnetic Resonance Imaging (MRI) scanning in Asian patients implanted the Ellipse MR Conditional ICD System - The ASIA MRI ICD Study. APHRS 2017; Abstract no. 40528.</citation>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICD</keyword>
  <keyword>Thoracic MRI Scan</keyword>
  <keyword>tachycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

